XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 15,735 $ 155,973 $ 106,367 $ 218,766
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 116,434 22,590 116,434
Development Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 2,453 26,097 19,672 60,325
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 108,434 22,590 108,434
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 45 66 156 245
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 1,369 14,061 8,263 20,138
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 579 $ 11,970 $ 9,750 $ 39,939